BFA
CLSD

BlackRock Fund Advisors’s Clearside Biomedical CLSD Stock Holding History

BlackRock Fund Advisors’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$4.93M Buy
36,745
+22,027
+150% +$5.53M ﹤0.01% 2941
2016
Q3 		$3.83M Buy
+14,718
New +$1.8M ﹤0.01% 2979

Other funds holding CLSD

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

BlackRock Fund Advisors's CLSD Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Clearside Biomedical (CLSD) stake by 150% in Q4 2016, buying an estimated $5.53M and bringing the position to 36,745 shares worth $4.93M. The position accounts for ﹤0.01% of the portfolio, ranked #2941.

BlackRock Fund Advisors first reported a position in CLSD in Q3 2016 and has held it in 2 quarters since. 62 funds tracked by Wall St. Rank hold CLSD as of Q4 2016.

  • BlackRock Fund Advisors held 36,745 shares of Clearside Biomedical worth $4.93M as of Q4 2016.
  • BlackRock Fund Advisors bought 22,027 Clearside Biomedical shares in Q4 2016, an estimated $5.53M.
  • Clearside Biomedical made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2941 holding.
  • BlackRock Fund Advisors first reported a position in Clearside Biomedical in Q3 2016 and has held it in 2 quarters since.
  • 62 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.